Login Register Cart 0
Generic placeholder image

Current Protein & Peptide Science

Editor-in-Chief

ISSN (Print): 1389-2037
ISSN (Online): 1875-5550

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Emicizumab as a Promising Form of Therapy for Type A Hemophilia - A Review of Current Knowledge from Clinical Trials

Author(s): Katarzyna Grabowska, Michalina Grzelak, Lin-Yong Zhao, Elżbieta Płuciennik, Zbigniew Pasieka, Mateusz Kciuk, Adrianna Gielecińska, Aleksander K. Smakosz, Żaneta Kałuzińska-Kołat and Damian Kołat*

Volume 25, Issue 9, 2024

Published on: 23 May, 2024

Page: [719 - 737] Pages: 19

DOI: 10.2174/0113892037294674240509094418

Price: $65

Abstract

Hemophilia is a plasma bleeding disorder characterized by a deficiency of certain blood clotting factors. The most common forms of this disease, i.e., type A and type B, affect approximately 400,000 people worldwide. Without appropriate treatment ensuring the proper coagulation cascade, this disease may lead to serious disability. Minimizing patient discomfort is possible via replacement therapy, consisting of the substitution of a missing coagulation factor via intravenous administration. Frequent medication and the risk related to factor inhibitors are significant disadvantages, necessitating the improvement of current therapies or the development of novel ones. This review examines the humanized bispecific antibody Emicizumab which ensures hemostasis by mimicking the action of the coagulation factor VIII, a deficiency of which causes type A hemophilia. The paper outlines the topic and then summarizes available clinical trials on Emicizumab in type A hemophilia. Several interventional clinical trials have found Emicizumab to be effective in decreasing bleeding episodes and raising patient satisfaction among various hemophilia A populations. Current Emicizumab-related trials are forecast to be completed between 2024 and 2030, and in addition to congenital hemophilia A, the trials cover acquired hemophilia A and patients playing sports. Providing a more comprehensive understanding of Emicizumab may revolutionize the management of hemophilia type A and improve quality of life. Conclusively, Emicizumab is a gentler therapy owing to subcutaneous delivery and fewer injections, which reduces injection-site reactions and makes therapy less burdensome, ultimately decreasing hospital visits and indirect costs.

« Previous Next »
Graphical Abstract

[1]
Callaghan, M.U.; Sidonio, R.; Pipe, S.W. Novel therapeutics for hemophilia and other bleeding disorders. Blood, 2018, 132(1), 23-30.
[http://dx.doi.org/10.1182/blood-2017-09-743385] [PMID: 29769259]
[2]
Windyga, J.; Chojnowski, K.; Klukowska, A.; Łętowska, M.; Mital, A.; Musiał, J.; Peregud-Pogorzelski, J.; Podolak-Dawidziak, M.; Treliński, J.; Undas, A.; Urasiński, T.; Zdziarska, J.; Zawilska, K.; Część, I. Część I: Wytyczne postępowania w hemofilii A i B niepowikłanej inhibitorem czynnika VIII i IX (wydanie zaktualizowane). Acta Haematol. Pol., 2016, 47(2), 86-114.
[http://dx.doi.org/10.1016/j.achaem.2016.04.009]
[3]
Kessler, C.M.; Knöbl, P. Acquired haemophilia: an overview for clinical practice. Eur. J. Haematol., 2015, 95(S81)(Suppl. 81), 36-44.
[http://dx.doi.org/10.1111/ejh.12689] [PMID: 26679396]
[4]
Sahu, S.; Lata, I.; Singh, S.; Kumar, M. Revisiting hemophilia management in acute medicine. J. Emerg. Trauma Shock, 2011, 4(2), 292-298.
[http://dx.doi.org/10.4103/0974-2700.82225] [PMID: 21769217]
[5]
Müller, J.; Miesbach, W.; Prüller, F.; Siegemund, T.; Scholz, U.; Sachs, U.J. An update on laboratory diagnostics in haemophilia A and B. Hamostaseologie, 2022, 42(4), 248-260.
[http://dx.doi.org/10.1055/a-1665-6232] [PMID: 35104901]
[6]
Nathwani, A.C. Gene therapy for hemophilia. Hematology (Am. Soc. Hematol. Educ. Program), 2022, 2022(1), 569-578.
[http://dx.doi.org/10.1182/hematology.2022000388] [PMID: 36485127]
[7]
Chuah, M.K.; Evens, H.; VandenDriessche, T. Gene therapy for hemophilia. J. Thromb. Haemost., 2013, 11(Suppl. 1), 99-110.
[http://dx.doi.org/10.1111/jth.12215] [PMID: 23809114]
[8]
Goodman, D.M.; Burke, A.E.; Livingston, E.H. Bleeding Disorders. JAMA, 2012, 308(14), 1492.
[http://dx.doi.org/10.1001/jama.2012.4089] [PMID: 23047368]
[9]
Mathews, R.; Issac, R.M. Bleeding and Coagulation Disorders.Clinical Pathways in Emergency Medicine; Springer, 2016, pp. 417-428.
[10]
Arrieta-Blanco, J.J.; Oñate-Sánchez, R.; Martínez-López, F.; Oñate-Cabrerizo, D.; Cabrerizo-Merino, M.C. Inherited, congenital and acquired disorders by hemostasis (vascular, platelet and plasmatic phases) with repercussions in the therapeutic oral sphere. Med. Oral Patol. Oral Cir. Bucal, 2014, 19(3), e280-e288.
[http://dx.doi.org/10.4317/medoral.19560] [PMID: 24121923]
[11]
Odnoczko, E.; Baran, B.; Windyga, J. Zasady rozpoznawania skaz krwotocznych ze szczególnym uwzględnieniem diagnostyki laboratoryjnej. Hematologia, 2017, 7(4), 303-311.
[http://dx.doi.org/10.5603/Hem.2016.0029]
[12]
Ndoumba-Mintya, A.; Diallo, Y.L.; Tayou, T.C.; Mbanya, D.N. Optimizing haemophilia care in resource-limited countries: Current challenges and future prospects. J. Blood Med., 2023, 14, 141-146.
[http://dx.doi.org/10.2147/JBM.S291536] [PMID: 36846349]
[13]
Lambert, C.; Meité, N.D.; Sanogo, I.; Lobet, S.; Adjambri, E.; Eeckhoudt, S.; Hermans, C. Hemophilia carrier’s awareness, diagnosis, and management in emerging countries: a cross-sectional study in Côte d’Ivoire (Ivory Coast). Orphanet J. Rare Dis., 2019, 14(1), 26.
[http://dx.doi.org/10.1186/s13023-019-1005-9] [PMID: 30709356]
[14]
Boylan, B.; Rice, A.S.; De Staercke, C.; Eyster, M.E.; Yaish, H.M.; Knoll, C.M.; Bean, C.J.; Miller, C.H.; Abshire, T.C.; Dunn, A.; Kempton, C.L.; Bockenstedt, P.L.; Brettler, D.B.; Di Paola, J.A.; Radhi, M.; Lentz, S.R.; Massey, G.; Barrett, J.C.; Neff, A.T.; Shapiro, A.D.; Tarantino, M.; Wicklund, B.M.; Manco-Johnson, M.J.; Escobar, M.A.; Gill, J.C.; Leissinger, C. Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations. J. Thromb. Haemost., 2015, 13(6), 1036-1042.
[http://dx.doi.org/10.1111/jth.12902] [PMID: 25780857]
[15]
Goodeve, A.C.; Rosén, S.; Verbruggen, B. Haemophilia A and von Willebrand’s disease. Haemophilia, 2010, 16(s5)(Suppl. 5), 79-84.
[http://dx.doi.org/10.1111/j.1365-2516.2010.02303.x] [PMID: 20590861]
[16]
Terraube, V.; O’Donnell, J.S.; Jenkins, P.V. Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance. Haemophilia, 2010, 16(1), 3-13.
[http://dx.doi.org/10.1111/j.1365-2516.2009.02005.x] [PMID: 19473409]
[17]
Bowen, D.J. Haemophilia A and haemophilia B: molecular insights. Mol. Pathol., 2002, 55(2), 127-144.
[http://dx.doi.org/10.1136/mp.55.2.127] [PMID: 11950963]
[18]
Tiede, A. Half-life extended factor VIII for the treatment of hemophilia A. J. Thromb. Haemost., 2015, 13(Suppl. 1), S176-S179.
[http://dx.doi.org/10.1111/jth.12929] [PMID: 26149020]
[19]
Goodeve, A.C. Hemophilia B: molecular pathogenesis and mutation analysis. J. Thromb. Haemost., 2015, 13(7), 1184-1195.
[http://dx.doi.org/10.1111/jth.12958] [PMID: 25851415]
[20]
Philip, J.; Sarkar, R.S.; Kumar, S.; Prathip, B.R.; Pathak, A. Factor IX deficiency (Christmas disease). Med. J. Armed Forces India, 2012, 68(4), 379-380.
[http://dx.doi.org/10.1016/j.mjafi.2011.12.007] [PMID: 24532909]
[21]
Lewandowska, M.D.; Connors, J.M.; Factor, X.I. Factor XI Deficiency. Hematol. Oncol. Clin. North Am., 2021, 35(6), 1157-1169.
[http://dx.doi.org/10.1016/j.hoc.2021.07.012] [PMID: 34535287]
[22]
Emsley, J.; McEwan, P.A.; Gailani, D. Structure and function of factor XI. Blood, 2010, 115(13), 2569-2577.
[http://dx.doi.org/10.1182/blood-2009-09-199182] [PMID: 20110423]
[23]
Franchini, M.; Veneri, D.; Lippi, G. Inherited factor XI deficiency: A concise review. Hematology, 2006, 11(5-6), 307-309.
[http://dx.doi.org/10.1080/10245330600921964] [PMID: 17607578]
[24]
Marino, R. Acquired hemophilia A: Bleeding pattern and hemostatic therapeutic strategies. Medicina (Kaunas), 2023, 59(10), 1739.
[http://dx.doi.org/10.3390/medicina59101739] [PMID: 37893457]
[25]
Sridharan, M.; Pruthi, R.K. Autoimmune (acquired) hemophilia: Updates in diagnosis and therapy. Hematology., 2022, 19(2), 2022214.
[26]
Yousphi, A.S.; Bakhtiar, A.; Cheema, M.A.; Nasim, S.; Ullah, W. Acquired hemophilia A: A rare but potentially fatal bleeding disorder. Cureus, 2019, 11(8), e5442.
[http://dx.doi.org/10.7759/cureus.5442] [PMID: 31632887]
[27]
Knobe, K.; Berntorp, E. Haemophilia and joint disease: Pathophysiology, evaluation, and management. J. Comorb., 2011, 1(1), 51-59.
[http://dx.doi.org/10.15256/joc.2011.1.2] [PMID: 29090136]
[28]
Touré, S.A.; Seck, M.; Sy, D.; Bousso, E.S.; Faye, B.F.; Diop, S. Life-threatening bleeding in patients with hemophilia (PWH): a 10-year cohort study in Dakar, Senegal. Hematology, 2022, 27(1), 379-383.
[http://dx.doi.org/10.1080/16078454.2022.2047286] [PMID: 35306964]
[29]
Gale, A.J. Continuing education course #2: current understanding of hemostasis. Toxicol. Pathol., 2011, 39(1), 273-280.
[http://dx.doi.org/10.1177/0192623310389474] [PMID: 21119054]
[30]
Sidonio, R.F., Jr; Hoffman, M.; Kenet, G.; Dargaud, Y. Thrombin generation and implications for hemophilia therapies: A narrative review. Res. Pract. Thromb. Haemost., 2023, 7(1), 100018.
[http://dx.doi.org/10.1016/j.rpth.2022.100018] [PMID: 36798897]
[31]
Pavlova, A.; Oldenburg, J. Defining severity of hemophilia: more than factor levels. Semin. Thromb. Hemost., 2013, 39(7), 702-710.
[http://dx.doi.org/10.1055/s-0033-1354426] [PMID: 24026911]
[32]
Al-Allaf, F.A.; Taher, M.M.; Abduljaleel, Z.; Bouazzaoui, A.; Athar, M.; Bogari, N.M.; Abalkhail, H.A.; Owaidah, T.M.A. Molecular analysis of factor VIII and factor IX Genes in hemophilia patients: Identification of novel mutations and molecular dynamics studies. J. Clin. Med. Res., 2017, 9(4), 317-331.
[http://dx.doi.org/10.14740/jocmr2876w] [PMID: 28270892]
[33]
Gooding, R.; Thachil, J.; Alamelu, J.; Motwani, J.; Chowdary, P. Asymptomatic joint bleeding and joint health in hemophilia: A review of variables, methods, and biomarkers. J. Blood Med., 2021, 12, 209-220.
[http://dx.doi.org/10.2147/JBM.S304597] [PMID: 33833602]
[34]
Bowyer, A.E.; Gosselin, R.C. Factor VIII and factor IX activity measurements for hemophilia diagnosis and related treatments. Semin. Thromb. Hemost., 2023, 49(6), 609-620.
[http://dx.doi.org/10.1055/s-0042-1758870] [PMID: 36473488]
[35]
Young, G.A.; Perry, D.J. Laboratory assay measurement of modified clotting factor concentrates: a review of the literature and recommendations for practice. J. Thromb. Haemost., 2019, 17(4), 567-573.
[http://dx.doi.org/10.1111/jth.14394] [PMID: 30667575]
[36]
Al Moosawi, M.; Nicolson, H.; Wong, S.K.W.; Dallas, K.L.; Jackson, S. Treatment changes in hemophilia A with chromogenic factor VIII assay implementation. Res. Pract. Thromb. Haemost., 2023, 7(2), 100098.
[http://dx.doi.org/10.1016/j.rpth.2023.100098] [PMID: 37063773]
[37]
Srivastava, A.; Brewer, A.K.; Mauser-Bunschoten, E.P.; Key, N.S.; Kitchen, S.; Llinas, A.; Ludlam, C.A.; Mahlangu, J.N.; Mulder, K.; Poon, M.C.; Street, A. Guidelines for the management of hemophilia. Haemophilia, 2013, 19(1), e1-e47.
[http://dx.doi.org/10.1111/j.1365-2516.2012.02909.x] [PMID: 22776238]
[38]
Jayakrishnan, T.; Shah, D.; Mewawalla, P.; Hemophilia, C. Hemophilia C: A case report with updates on diagnosis and management of a rare bleeding disorder. J. Hematol. (Brossard), 2019, 8(3), 144-147.
[http://dx.doi.org/10.14740/jh522] [PMID: 32300461]
[39]
Zanon, E. Acquired hemophilia A: An update on the etiopathogenesis, diagnosis, and treatment. Diagnostics (Basel), 2023, 13(3), 420.
[http://dx.doi.org/10.3390/diagnostics13030420] [PMID: 36766524]
[40]
Tiede, A.; Collins, P.; Knoebl, P.; Teitel, J.; Kessler, C.; Shima, M.; Di Minno, G.; d’Oiron, R.; Salaj, P.; Jiménez-Yuste, V.; Huth-Kühne, A.; Giangrande, P. International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica, 2020, 105(7), 1791-1801.
[http://dx.doi.org/10.3324/haematol.2019.230771] [PMID: 32381574]
[41]
Jiménez-Yuste, V.; Auerswald, G.; Benson, G.; Lambert, T.; Morfini, M.; Remor, E.; Salek, S.Z. Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future. Blood Transfus., 2014, 12(3), 314-319.
[PMID: 25074524]
[42]
Malec, L.; Matino, D. Targeting higher factor VIII levels for prophylaxis in haemophilia A: A narrative review. Haemophilia, 2023, 29(6), 1419-1429.
[http://dx.doi.org/10.1111/hae.14866] [PMID: 37758651]
[43]
Auerswald, G.; Dolan, G.; Duffy, A.; Hermans, C.; Jiménez-Yuste, V.; Ljung, R.; Morfini, M.; Lambert, T.; Šalek, S.Z. Pain and pain management in haemophilia. Blood Coagul. Fibrinolysis, 2016, 27(8), 845-854.
[http://dx.doi.org/10.1097/MBC.0000000000000571] [PMID: 27439216]
[44]
Meeks, S.L.; Batsuli, G. Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches. Hematology (Am. Soc. Hematol. Educ. Program), 2016, 2016(1), 657-662.
[http://dx.doi.org/10.1182/asheducation-2016.1.657] [PMID: 27913543]
[45]
Swiech, K.; Picanço-Castro, V.; Covas, D.T. Production of recombinant coagulation factors: Are humans the best host cells? Bioengineered, 2017, 8(5), 462-470.
[http://dx.doi.org/10.1080/21655979.2017.1279767] [PMID: 28277160]
[46]
Gelbenegger, G.; Schoergenhofer, C.; Knoebl, P.; Jilma, B. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A. Thromb. Haemost., 2020, 120(10), 1357-1370.
[http://dx.doi.org/10.1055/s-0040-1714279] [PMID: 32717759]
[47]
Morfini, M.; Coppola, A.; Franchini, M.; Di Minno, G. Clinical use of factor VIII and factor IX concentrates. Blood Transfus., 2013, 11(Suppl 4), S55-S63.
[48]
Oldenburg, J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood, 2015, 125(13), 2038-2044.
[http://dx.doi.org/10.1182/blood-2015-01-528414] [PMID: 25712992]
[49]
Mannucci, P.M. Benefits and limitations of extended plasma half-life factor VIII products in hemophilia A. Expert Opin. Investig. Drugs, 2020, 29(3), 303-309.
[http://dx.doi.org/10.1080/13543784.2020.1723547] [PMID: 31990229]
[50]
Witmer, C.; Young, G. Factor VIII inhibitors in hemophilia A: Rationale and latest evidence. Ther. Adv. Hematol., 2013, 4(1), 59-72.
[http://dx.doi.org/10.1177/2040620712464509] [PMID: 23610614]
[51]
Peyvandi, F.; Garagiola, I.; Abbattista, M. Fitusiran in haemophilia: A breakthrough drug with many unknowns. Lancet, 2023, 401(10386), 1400-1401.
[http://dx.doi.org/10.1016/S0140-6736(23)00514-7] [PMID: 37003290]
[52]
Franchini, M.; Mannucci, P.M. Non-factor replacement therapy for haemophilia: A current update. Blood Transfus., 2018, 16(5), 457-461.
[PMID: 29517971]
[53]
Machin, N.; Ragni, M.V.; Smith, K.J. Gene therapy in hemophilia A: A cost-effectiveness analysis. Blood Adv., 2018, 2(14), 1792-1798.
[http://dx.doi.org/10.1182/bloodadvances.2018021345] [PMID: 30042145]
[54]
Miesbach, W.; Schwäble, J.; Müller, M.M.; Seifried, E. Treatment options in hemophilia. Dtsch. Arztebl. Int., 2019, 116(47), 791-798.
[PMID: 31847949]
[55]
De Wolf, D.; Singh, K.; Chuah, M.K.; VandenDriessche, T. Hemophilia gene therapy: The end of the beginning? Hum. Gene Ther., 2023, 34(17-18), 782-792.
[http://dx.doi.org/10.1089/hum.2023.112] [PMID: 37672530]
[56]
Yu, J.K.; Wong, W.W.L.; Keepanasseril, A.; Iorio, A.; Edginton, A.N. Cost-utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada. Haemophilia, 2023, 29(2), 488-497.
[http://dx.doi.org/10.1111/hae.14723] [PMID: 36528890]
[57]
Bayer, V. An overview of monoclonal antibodies. Semin. Oncol. Nurs., 2019, 35(5), 150927.
[http://dx.doi.org/10.1016/j.soncn.2019.08.006] [PMID: 31488319]
[58]
Effer, B.; Perez, I.; Ulloa, D.; Mayer, C.; Muñoz, F.; Bustos, D.; Rojas, C.; Manterola, C.; Vergara-Gómez, L.; Dappolonnio, C.; Weber, H.; Leal, P. Therapeutic targets of monoclonal antibodies used in the treatment of cancer: Current and emerging. Biomedicines, 2023, 11(7), 2086.
[http://dx.doi.org/10.3390/biomedicines11072086] [PMID: 37509725]
[59]
Superson, M.; Szmyt, K.; Szymańska, K.; Walczak, K.; Wnorowski, J.; Zarębski, Ł. Clinical application of monoclonal antibodies in targeted therapy. Eur. J. Clin. Exp. Med., 2020, 17(4), 338-346.
[http://dx.doi.org/10.15584/ejcem.2019.4.9]
[60]
Chen, W.; Li, X.; Guo, M.; Link, F.J.; Ramli, S.S.; Ouyang, J.; Rosbottom, I.; Heng, J.Y.Y. Biopurification of monoclonal antibody (mAb) through crystallisation. Separ. Purif. Tech., 2021, 263, 118358.
[http://dx.doi.org/10.1016/j.seppur.2021.118358]
[61]
Segués, A.; Huang, S.; Sijts, A.; Berraondo, P.; Zaiss, D.M. Opportunities and challenges of bi-specific antibodies. Int. Rev. Cell Mol. Biol., 2022, 369, 45-70.
[http://dx.doi.org/10.1016/bs.ircmb.2022.05.001] [PMID: 35777864]
[62]
Lenting, P.J.; Denis, C.V.; Christophe, O.D. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: How does it actually compare to factor VIII? Blood, 2017, 130(23), 2463-2468.
[http://dx.doi.org/10.1182/blood-2017-08-801662] [PMID: 29042366]
[63]
Kitazawa, T.; Shima, M. Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity. Int. J. Hematol., 2020, 111(1), 20-30.
[http://dx.doi.org/10.1007/s12185-018-2545-9] [PMID: 30350119]
[64]
Kotani, N.; Yoneyama, K.; Kawakami, N.; Shimuta, T.; Fukase, H.; Kawanishi, T. Relative and absolute bioavailability study of emicizumab to bridge drug products and subcutaneous injection sites in healthy volunteers. Clin. Pharmacol. Drug Dev., 2019, 8(6), 702-712.
[http://dx.doi.org/10.1002/cpdd.617] [PMID: 30230257]
[65]
Donners, A.A.M.T.; van der Zwet, K.; Rademaker, C.M.A.; Egberts, T.C.G.; Schutgens, R.E.G.; Fischer, K. The efficacy of the entire-vial dosing of emicizumab: Real-world evidence on plasma concentrations, bleeds, and drug waste. Res. Pract. Thromb. Haemost., 2023, 7(2), 100074.
[http://dx.doi.org/10.1016/j.rpth.2023.100074] [PMID: 36915864]
[66]
Kitazawa, T.; Esaki, K.; Tachibana, T.; Ishii, S.; Soeda, T.; Muto, A.; Kawabe, Y.; Igawa, T.; Tsunoda, H.; Nogami, K.; Shima, M.; Hattori, K. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb. Haemost., 2017, 117(7), 1348-1357.
[http://dx.doi.org/10.1160/TH17-01-0030] [PMID: 28451690]
[67]
Yoneyama, K.; Schmitt, C.; Portron, A.; Kiialainen, A.; Kotani, N.; Jaminion, F.; Retout, S.; Adamkewicz, J.I. Clinical pharmacology of emicizumab for the treatment of hemophilia A. Expert Rev. Clin. Pharmacol., 2023, 16(9), 775-790.
[http://dx.doi.org/10.1080/17512433.2023.2243213] [PMID: 37529848]
[68]
Klamroth, R.; Wojciechowski, P.; Aballéa, S.; Diamand, F.; Hakimi, Z.; Nazir, J.; Abad-Franch, L.; Lethagen, S.; Santagostino, E.; Tarantino, M.D. Efficacy of rFVIIIFc versus emicizumab for the treatment of patients with hemophilia a without inhibitors: Matching-adjusted indirect comparison of A-LONG and HAVEN trials. J. Blood Med., 2021, 12, 115-122.
[http://dx.doi.org/10.2147/JBM.S288283] [PMID: 33664606]
[69]
Potnis, K.C.; Viswanathan, G.; Bona, R.D.; Ito, S.; Kempton, C.L.; Pandya, A.; Krumholz, H.M.; Goshua, G. Cost-effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States. Am. J. Hematol., 2023, 98(9), E247-E250.
[http://dx.doi.org/10.1002/ajh.27014] [PMID: 37401660]
[70]
Kitazawa, T.; Yoneyama, K.; Igawa, T. Discovery and development of emicizumab (HEMLIBRA®): A humanized bispecific antibody to coagulation factors IXa and X with a factor VIII cofactor activity. Successful Drug Discovery; Wiley online library, 2021, pp. 221-248.
[71]
Yada, K.; Nogami, K. Novel insights and new developments regarding coagulation revealed by studies of the anti-factor IXa (activated factor IX)/factor X bispecific antibody, emicizumab. Arterioscler. Thromb. Vasc. Biol., 2020, 40(5), 1148-1154.
[http://dx.doi.org/10.1161/ATVBAHA.120.312919] [PMID: 32237902]
[72]
Hermans, C.; Makris, M. Disruptive technology and hemophilia care: The multiple impacts of emicizumab. Res. Pract. Thromb. Haemost., 2021, 5(4), e12508.
[http://dx.doi.org/10.1002/rth2.12508] [PMID: 34027289]
[73]
Lenting, P.J. Laboratory monitoring of hemophilia A treatments: new challenges. Blood Adv., 2020, 4(9), 2111-2118.
[http://dx.doi.org/10.1182/bloodadvances.2019000849] [PMID: 32396619]
[74]
López-Jaime, F.J.; Benítez, O.; Díaz Jordán, B.L.; Montaño, A.; Coll, J.; Quintana París, L.; Gómez-del Castillo Solano, M.D.C. Expert opinion paper on the treatment of hemophilia A with emicizumab. Hematology, 2023, 28(1), 2166334.
[http://dx.doi.org/10.1080/16078454.2023.2166334] [PMID: 36636993]
[75]
Franchini, M.; Marano, G.; Veropalumbo, E.; Masiello, F.; Pati, I.; Candura, F.; Profili, S.; Catalano, L.; Piccinini, V.; Pupella, S.; Vaglio, S.; Liumbruno, G.M. Patient Blood Management: a revolutionary approach to transfusion medicine. Blood Transfus., 2019, 17(3), 191-195.
[PMID: 31246561]
[76]
Müller, J.; Pekrul, I.; Pötzsch, B.; Berning, B.; Oldenburg, J.; Spannagl, M. Laboratory monitoring in emicizumab-treated persons with hemophilia A. Thromb. Haemost., 2019, 119(9), 1384-1393.
[http://dx.doi.org/10.1055/s-0039-1692427] [PMID: 31203578]
[77]
Shima, M. Bispecific Antibodies and Advances in Non–Gene Therapy Options in Hemophilia. Res. Pract. Thromb. Haemost., 2020, 4(4), 446-454.
[http://dx.doi.org/10.1002/rth2.12337] [PMID: 32548546]
[78]
Owaidah, T.; Almomen, A.; Tarawah, A.; Warsi, A.; Alkasim, F.; Alzahrani, H.; Saleh, M.; Kashari, O.; Jastaniah, W. Consensus recommendations on appropriate coagulation tests during emicizumab administration in Saudi Arabia. Am. J. Blood Res., 2022, 12(3), 82-87.
[PMID: 35873100]
[79]
Kruse-Jarres, R.; Peyvandi, F.; Oldenburg, J.; Chang, T.; Chebon, S.; Doral, M.Y.; Croteau, S.E.; Lambert, T.; Kempton, C.L.; Pipe, S.W.; Ko, R.H.; Trzaskoma, B.; Dhalluin, C.; Bienz, N.S.; Niggli, M.; Lehle, M.; Paz-Priel, I.; Young, G.; Jiménez-Yuste, V. Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: Experience from the HAVEN 1-4 studies. Blood Adv., 2022, 6(24), 6140-6150.
[http://dx.doi.org/10.1182/bloodadvances.2022007458] [PMID: 35939785]
[80]
Evans, M.S.; Davis, C., III; Eyster, M.E. Total knee replacement with and without emicizumab: A unique comparison of perioperative management. Blood Adv., 2020, 4(5), 855-857.
[http://dx.doi.org/10.1182/bloodadvances.2019001060] [PMID: 32126140]
[81]
Lewandowska, M.; Randall, N.; Bakeer, N.; Maahs, J.; Sagar, J.; Greist, A.; Shapiro, A.D. Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real-world experience from a large comprehensive treatment centre in the US. Haemophilia, 2021, 27(1), 90-99.
[http://dx.doi.org/10.1111/hae.14212] [PMID: 33245841]
[82]
Srivastava, A.; Santagostino, E.; Dougall, A.; Kitchen, S.; Sutherland, M.; Pipe, S.W.; Carcao, M.; Mahlangu, J.; Ragni, M.V.; Windyga, J. WFH Guidelines for the Management of Hemophilia; World Federation of Hemophilia.: Canada, 2020.
[83]
Belletrutti, M.; Bhatt, M.; Samji, N. Management of children with hemophilia A on emicizumab who need surgery. Front Pediatr., 2023, 11, 1155853.
[http://dx.doi.org/10.3389/fped.2023.1155853] [PMID: 37082707]
[84]
Wieland, I. Emicizumab for All Pediatric Patients with Severe Hemophilia A. Hamostaseologie, 2022, 42(2), 104-115.
[http://dx.doi.org/10.1055/a-1727-1384] [PMID: 35488163]
[85]
Mancuso, M.E.; Holstein, K.; O’Donnell, J.S.; Lobet, S.; Klamroth, R.; Group, F.T.T.S. Synovitis and joint health in patients with haemophilia: Statements from a European e-Delphi consensus study. Haemophilia, 2023, 29(2), 619-628.
[http://dx.doi.org/10.1111/hae.14734] [PMID: 36622258]
[86]
Kuijlaars, I.A.R.; Timmer, M.A.; de Kleijn, P.; Pisters, M.F.; Fischer, K. Monitoring joint health in haemophilia: Factors associated with deterioration. Haemophilia, 2017, 23(6), 934-940.
[http://dx.doi.org/10.1111/hae.13327] [PMID: 28873289]
[87]
Wyseure, T.; Mosnier, L.O.; von Drygalski, A. Advances and challenges in hemophilic arthropathy. Semin. Hematol., 2016, 53(1), 10-19.
[http://dx.doi.org/10.1053/j.seminhematol.2015.10.005] [PMID: 26805902]
[88]
Kiialainen, A.; Niggli, M.; Kempton, C.L.; Castaman, G.; Chang, T.; Paz-Priel, I.; Adamkewicz, J.I.; Levy, G.G. Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study. Haemophilia, 2022, 28(6), 1033-1043.
[http://dx.doi.org/10.1111/hae.14642] [PMID: 35905294]
[89]
Ambrosio, M.R.; Aliberti, L.; Gagliardi, I.; Franceschetti, P.; Zatelli, M.C. Bone health in adolescence. Minerva Obstet. Gynecol., 2021, 73(6), 662-677.
[http://dx.doi.org/10.23736/S2724-606X.20.04713-9] [PMID: 34905874]
[90]
Genentech, Inc. Bleeding and Clotting Disorders Institute Peoria. Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A (BCDI-XII). NCT05500807, 2022.
[91]
Barg, A.A.; Avishai, E.; Budnik, I.; Brutman, T.B.; Tamarin, I.; Dardik, R.; Bashari, D.; Misgav, M.; Lubetsky, A.; Lalezari, S.; Livnat, T.; Kenet, G. The potential role of emicizumab prophylaxis in severe von Willebrand disease. Blood Cells Mol. Dis., 2021, 87, 102530.
[http://dx.doi.org/10.1016/j.bcmd.2020.102530] [PMID: 33341070]
[92]
Murray, N.P.; Ilabaca, J.; Guzman, E.; Orrega, S. Management of mild congenital deficiency of Factor XI with a Factor XI inhibitor in pregnancy: A clinical case. Hematol. Transfus. Cell Ther., 2022, 44(3), 444-446.
[http://dx.doi.org/10.1016/j.htct.2021.01.003] [PMID: 33622647]
[93]
Minami, H.; Nogami, K.; Yada, K.; Ogiwara, K.; Furukawa, S.; Soeda, T.; Kitazawa, T.; Shima, M. Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI-deficient plasma in vitro. J. Thromb. Haemost., 2019, 17(1), 126-137.
[http://dx.doi.org/10.1111/jth.14334] [PMID: 30444568]
[94]
Ogiwara, K.; Minami, H.; Nogami, K.; Matsumoto, T.; Kitazawa, T.; Hattori, K.; Shima, M. Anti FIXa/FX bispecific antibody (emicizumab) enhances plasma procoagulant activity in hemophilia B in the presence of very low level of factor IX. Res. Pract. Thromb. Haemost., 2017, 1(Suppl. 1), 749.
[95]
Valls, R.; Wagg, J.; Paz-Priel, I.; Man, G.; Artigas, L.; Jaccard, G.; Coma, M.; Schmitt, C. Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex concentrate and emicizumab. Sci. Rep., 2023, 13(1), 10078.
[http://dx.doi.org/10.1038/s41598-023-36891-x] [PMID: 37344529]
[96]
Hoffmann-La Roche. A study to evaluate the efficacy, safety, and pharmacokinetics of prophylactic emicizumab versus no prophylaxis in hemophilia A participants with inhibitors (HAVEN 1). NCT02622321., 2015.
[97]
Hoffmann-La Roche. A study of emicizumab administered subcutaneously (SC) in pediatric participants with hemophilia A and factor VIII (FVIII) inhibitors (HAVEN 2). NCT02795767., 2016.
[98]
Johnny, M.M.B.; Oldenburg, J.; Negrier, C. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N. Engl. J. Med., 2016, 379, 811-822.
[99]
Hoffmann-La Roche. a multicenter, open-label, phase iii study to evaluate the efficacy, safety, pharmacokinetics,and pharmacodynamics of emicizumab given every 4 weeks (q4w) in patients with hemophilia A. NCT03020160., 2017.
[100]
Callaghan, M.U.; Negrier, C.; Paz-Priel, I.; Chang, T.; Chebon, S.; Lehle, M.; Mahlangu, J.; Young, G.; Kruse-Jarres, R.; Mancuso, M.E.; Niggli, M.; Howard, M.; Bienz, N.S.; Shima, M.; Jiménez-Yuste, V.; Schmitt, C.; Asikanius, E.; Levy, G.G.; Pipe, S.W.; Oldenburg, J. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood, 2021, 137(16), 2231-2242.
[http://dx.doi.org/10.1182/blood.2020009217] [PMID: 33512413]
[101]
Shima, M.; Nogami, K.; Nagami, S.; Yoshida, S.; Yoneyama, K.; Ishiguro, A.; Suzuki, T.; Taki, M. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors. Haemophilia, 2019, 25(6), 979-987.
[http://dx.doi.org/10.1111/hae.13848] [PMID: 31515851]
[102]
Hoffmann-La Roche. A study to evaluate the safety and tolerability of prophylactic emicizumab in hemophilia A patients with inhibitors (STASEY). NCT03191799., 2017.
[103]
Jiménez-Yuste, V.; Peyvandi, F.; Klamroth, R.; Castaman, G.; Shanmukhaiah, C.; Rangarajan, S.; García Chavez, J.; Martinez, R.; Kenet, G.; Alzahrani, H.; Robson, S.; Schmitt, C.; Kiialainen, A.; Meier, O.; Ozelo, M. Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single-arm study (STASEY). Res. Pract. Thromb. Haemost., 2022, 6(8), e12837.
[http://dx.doi.org/10.1002/rth2.12837] [PMID: 36397934]
[104]
Cliniques universitaires Saint-Luc-Université Catholique de Louvain. Outcomes of Prophylaxis With Emicizumab in Children With Severe Hemophilia A in Ivory Coast. NCT05279924., 2021.
[105]
Lambert, C.; Meité, N.D.; Kouassi, G.K.; Dohoma, A.S.; Bognini Akou, S.A.; Sanogo, I.; Hermans, C. Nonreplacement therapy for hemophilia in low-income countries: experience from a prospective study in Ivory Coast. Res. Pract. Thromb. Haemost., 2023, 7(1), 100033.
[http://dx.doi.org/10.1016/j.rpth.2022.100033] [PMID: 36785756]
[106]
Ogiwara, K.; Taki, M.; Suzuki, T.; Takedani, H.; Matsushita, T.; Amano, K.; Matsumoto, M.; Nishio, K.; Shima, M.; Kasahara, M.; Nogami, K. Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial. BMJ Open, 2022, 12(2), e056922.
[http://dx.doi.org/10.1136/bmjopen-2021-056922] [PMID: 35177463]
[107]
Kenichi Ogiwara, Nara Medical University Hospital. HemophiliaA with Inhibitor. jRCTs051190119, 2020. Available from: https://rctportal.niph.go.jp/en/detail?trial_id=jRCTs051190119
[108]
Hoffmann-La R.. Emicizumab in Acquired Hemophilia A. NCT04188639, 2021.
[109]
Tiede, A.; Hart, C.; Knöbl, P.; Greil, R.; Oldenburg, J.; Sachs, U.J.; Miesbach, W.; Pfrepper, C.; Trautmann-Grill, K.; Holstein, K.; Pilch, J.; Möhnle, P.; Schindler, C.; Weigt, C.; Schipp, D.; May, M.; Dobbelstein, C.; Pelzer, F.J.; Werwitzke, S.; Klamroth, R. Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): An open-label, single-arm, multicentre, phase 2 study. Lancet Haematol., 2023, 10(11), e913-e921.
[http://dx.doi.org/10.1016/S2352-3026(23)00280-6] [PMID: 37858328]
[110]
Wojciechowska, U.; Barańska, K.; Miklewska, M.; Didkowska, J.A. Cancer incidence and mortality in Poland in 2020. Nowotwory. Journal of Oncology, 2023, 73(3), 129-145.
[http://dx.doi.org/10.5603/NJO.2023.0026]
[111]
Shima, M.; Amano, K.; Ogawa, Y.; Yoneyama, K.; Ozaki, R.; Kobayashi, R.; Sakaida, E.; Saito, M.; Okamura, T.; Ito, T.; Hattori, N.; Higasa, S.; Suzuki, N.; Seki, Y.; Nogami, K. A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A. J. Thromb. Haemost., 2023, 21(3), 534-545.
[http://dx.doi.org/10.1016/j.jtha.2022.10.004] [PMID: 36696195]
[112]
Margaret Ragni. Hemophilia inhibitor clinical trials (INHIBIT) platform (INHIBIT). NCT02196207, 2020.
[113]
Margaret Ragni.. The Hemophilia Inhibitor Eradication Trial. NCT04303572, 2021.
[114]
Margaret Ragni.. The hemophilia inhibitor prevention trial. NCT04303559, 2021.
[115]
Hoffmann-La R.. Efficacy, safety, and pharmacokinetic study of prophylactic emicizumab versus no prophylaxis in hemophilia A participants (HAVEN 5) NCT03315455, 2018.
[116]
Yang, R.; Wang, S.; Wang, X.; Sun, J.; Chuansumrit, A.; Zhou, J.; Schmitt, C.; Hsu, W.; Xu, J.; Li, L.; Chang, T.; Zhao, X. Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: A randomized study (HAVEN 5). Res. Pract. Thromb. Haemost., 2022, 6(2), e12670.
[http://dx.doi.org/10.1002/rth2.12670] [PMID: 35284778]
[117]
Hoffmann-La Roche. A study to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of emicizumab in participants with mild or moderate hemophilia A without FVIII inhibitors (HAVEN 6). NCT04158648, 2020.
[118]
Négrier, C.; Mahlangu, J.; Lehle, M.; Chowdary, P.; Catalani, O.; Bernardi, R.J.; Jiménez-Yuste, V.; Beckermann, B.M.; Schmitt, C.; Ventriglia, G.; Windyga, J.; d’Oiron, R.; Moorehead, P.; Koparkar, S.; Teodoro, V.; Shapiro, A.D.; Oldenburg, J.; Hermans, C. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): A multicentre, open-label, single-arm, phase 3 study. Lancet Haematol., 2023, 10(3), e168-e177.
[http://dx.doi.org/10.1016/S2352-3026(22)00377-5] [PMID: 36716761]
[119]
Hoffmann-La Roche. A study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous emicizumab in participants from birth to 12 months of age with hemophilia A without inhibitors (HAVEN 7). NCT04431726, 2021.
[120]
Pipe, S.W.; Collins, P.; Dhalluin, C.; Kenet, G.; Schmitt, C.; Buri, M.; Jiménez-Yuste, V.; Peyvandi, F.; Young, G.; Oldenburg, J.; Mancuso, M.E.; Kiialainen, A.; Chang, T.; Lehle, M.; Fijnvandraat, K. Emicizumab prophylaxis for the treatment of infants with severe hemophilia A without factor VIII inhibitors: Results from the interim analysis of the HAVEN 7 study. Blood, 2022, 140(Suppl. 1), 457-459.
[http://dx.doi.org/10.1182/blood-2022-157264]
[121]
Shima, M.; Takedani, H.; Kitsukawa, K.; Taki, M.; Ishiguro, A.; Nagae, C.; Nagao, A.; Nosaka, D.; Kyogoku, Y.; Oki, H.; Iwasaki, K.; Nogami, K. Three-year interim analysis results of the AOZORA study to evaluate the long-term safety and joint health in children with hemophilia A without factor VIII inhibitors receiving emicizumab. Blood, 2023, 142(Suppl. 1), 3991-3991.
[http://dx.doi.org/10.1182/blood-2023-173073]
[122]
Shima, M.; Takedani, H.; Kitsukawa, K.; Taki, M.; Ishiguro, A.; Nagao, A.; Yamaguchi-Suita, H.; Kyogoku, Y.; Yoshida, S.; Nogami, K. AOZORA: long-term safety and joint health in paediatric persons with haemophilia A without factor VIII inhibitors receiving emicizumab – protocol for a multicentre, open-label, phase IV clinical study. BMJ Open, 2022, 12(6), e059667.
[http://dx.doi.org/10.1136/bmjopen-2021-059667] [PMID: 35697445]
[123]
Nogami, K.; Fujii, T.; Sawada, A.; Nagao, A.; Nagae, C.; Nojima, M.; Suzuki, N.; Nosaka, D.; Shimura, T.; Sugao, Y.; Amano, K. Association of physical activity with bleeding events and safety in patients with haemophilia A starting emicizumab prophylaxis: an interim analysis of the TSUBASA study. Int. J. Hematol., 2024, 119(1), 14-23.
[http://dx.doi.org/10.1007/s12185-023-03679-8] [PMID: 38100026]
[124]
Indiana Hemophilia, Thrombosis Center, Inc.. Hemlibra in mild hemophilia A. NCT04567511, 2021.
[125]
Rebecca Kruse-Jarres, University of Washington. Emicizumab in patients with acquired hemophilia A (AHAEmi). NCT05345197, 2022.
[126]
Pharmaceutical JW. The safety of emicizumab SC injection in Korean hemophilia A patients with/without FVIII inhibitors. NCT04805801, 2019.
[127]
Grenoble University Hospital. Impact of emicizumab on activated clotting time using the i-STAT alinity analyzer (EMISTAT). NCT05856903, 2023.
[128]
Capdevila, L.; Frère, C.; Desvages, M.; Harroche, A.; Bally, C.; Abbes, A.; d’Oiron, R.; Frenzel, L.; Borgel, D.; Lasne, D. Emicizumab does not interfere with the activated clotting time. Haemophilia, 2022, 28(2), 362-366.
[http://dx.doi.org/10.1111/hae.14497] [PMID: 35060654]
[129]
Jessica Garcia, University of Texas Southwestern Medical Center. POCUS: Hemostatic potential and joint health in patients with severe Hemophilia A on novel replacement therapies. NCT04690322, 2021.
[130]
Rebecca Kruse-Jarres, Washington Institute for Coagulation. Effects of emicizumab NCT04131036, 2019.
[131]
Hoffmann-La Roche. A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis (Beyond ABR). NCT05181618, 2022.
[132]
Meera Chitlur, Wayne State University. Prevention of bleeding in patients with moderate and severe hemophilia A playing sports: A Comparison between factor VIII and emicizumab prophylaxis (STEP). NCT05022459, 2023.
[133]
Emory University. Treatment of hemophilia A patients with FVIII inhibitors (MOTIVATE). NCT04023019, 2020.
[134]
Goethe University.. Dynamics of the anti-factor VIII antibody signature during treatment with emicizumab (NAVIGATE). NCT05802836, 2023.
[135]
Shoko Furukawa, Nara Medical University Hospital. Hemophilia A in infancy and newborns; multi-institutional prospective observational study to assess the efficacy and safety of emicizumab (HINODE). jRCT1031230264, 2023.

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy